At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 64 enrolled
Drug / intervention
Saxagliptin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Previous Metformin Treatment
In Brief
A Phase 4 clinical trial evaluating Saxagliptin and Placebo for Saxagliptin for Type2 Diabetes Mellitus. Completed, enrolled 64 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate alpha- and beta-cell function during combination treatment with saxagliptin in addition to dapagliflozin and metformin compared to placebo in addition to dapagliflozin and metformin in subjects with T2DM on stable metformin background therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType2 Diabetes Mellitus
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionAug 2016
TodayJul 2026
First PostedDec 1, 2014
Enrollment StartJan 1, 2015
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.6 years ago
Interventions
Saxagliptindrug
competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
Placebo for Saxagliptindrug